<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976115</url>
  </required_header>
  <id_info>
    <org_study_id>DDO-3055-101</org_study_id>
    <nct_id>NCT03976115</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Dose-escalating, Placebo Controlled, Phase I Study to Evaluate the Safety and Pharmacokinetics and Pharmacodynamics of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to
      evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers
      and patients with chronic kidney disease.

      48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease
      will be enrolled in Part B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events(AEs) and Serious Adverse Events （SAEs）</measure>
    <time_frame>from informed consent form signature to the end of the study (up to 14 days)</time_frame>
    <description>Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (tmax) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination half-life (t1/2) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance of the drug from plasma after oral administration (CL/F) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution after non-intravenous administration (V/F) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of the drug from plasma (CLR) of DDO-3055</measure>
    <time_frame>Pre-dose to 72 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in red blood cell count relative to baseline</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in reticulocyte count relative to baseline</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemoglobin relative to baseline</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in endogenous erythropoietin relative to baseline</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1. healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3x single dose of DDO-3055 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Patients with chronic kidney disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3x single dose of DDO-3055 and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDO-3055</intervention_name>
    <description>Oral</description>
    <arm_group_label>1. healthy volunteers</arm_group_label>
    <arm_group_label>2. Patients with chronic kidney disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oral</description>
    <arm_group_label>1. healthy volunteers</arm_group_label>
    <arm_group_label>2. Patients with chronic kidney disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers:

        Male or female volunteers aged 18 to 45 years of age inclusive ; Hemoglobin is 120 to 160
        g/L; In good health, at the discretion of the investigator, as determined by: medical
        history, physical examination, vital sign assessment, 12-lead ECG, clinical laboratory
        evaluations.

        - Patients with chronic kidney disease : Male or female patients with chronic kidney
        disease who are 18 to 45 years of age inclusive; Hemoglobin is ≤100 g/L; 30mL/min/1.73m2 ≤
        eGFR ≤ 60mL/min/1.73m2（according to CKD-EPI formula）;

          -  Body weight is ≥ 50kg, and 19kg/m2 ≤ body mass index&lt;26kg/m2 .

          -  Normal iron reserves (serum iron &gt;61 g/dL and serum ferritin normal &gt;30ng/mL).

          -  Signed informed consent.

        Exclusion Criteria:

        Healthy volunteers:

        - The serum creatinine exceeded the upper limit of normal value in the screening period.

        Healthy volunteers and patients with chronic kidney disease:

          -  Allergic to the study drug or any of its ingredients.

          -  Treating or treated with erythropoiesis stimulating agents for 1 month before
             screening.

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl
             transferase (GGT) or total bilirubin above 1.5 times normal upper limit (ULN) in the
             screening period.

          -  Have a history of blood donation or blood transfusion within 3 months.

          -  Vein blood collection is difficult or physical condition can not afford blood
             collection.

          -  Hepatitis b surface antigen (HBsAg), hepatitis c antibody (HCVAb), syphilis antibody,
             or human immunodeficiency virus (HIV) antibody test is positive in the screening
             period.

          -  Smoking 5 cigarettes per day on average within 3 months; or the average daily intake
             of alcohol within one week is more than 15g (15g alcohol is equivalent to 450mL beer
             or 150mL wine or 50mL low-alcohol liquor) or 2 days before taking the study drug and
             during the study period, tobacco, alcohol and caffeinated food or beverage are not
             prohibited, or those with special dietary requirements cannot comply with the unified
             diet.

          -  Those who have participated in clinical trials of any drug or medical device within 3
             months prior to screening, or those who have participated in the drug trial within 5
             half-lives prior to screening; any health product (within 1 week prior to
             administration), over-the-counter drug (2 weeks prior to administration) or
             prescription drug (1 month prior to administration) that affects the absorption,
             distribution, metabolism or excretion of the tested drug.

          -  With a history of drug abuse or positive screening/baseline test for substance abuse
             and drug urinalysis.

          -  During the study period and within 30 days after administration, men who are unwilling
             to take contraceptive measures and promise not to donate sperm are not allowed to
             participate in the study. Childbearing women who did not use contraception at least 14
             days before administration; men and women who did not agree to use physical
             contraception during the study period.

          -  Women with serum HCG ≥ 5 mIU/mL or nursing in the screening period or baseline

          -  Any physical or mental illness or condition that may increase the risk of the study,
             affect the subject's compliance with the protocol, or affect the subject's ability to
             complete the study, as determined by the study physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weifang Zeng</last_name>
    <phone>18036617101</phone>
    <email>zengweifang@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqing Yu</last_name>
      <email>yuxq@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

